CytoMed Therapeutics (US:GDTC) Globenewswire·2025-11-06 13:00Core Insights - CytoMed Therapeutics Limited has secured a non-dilutive investment of up to US$500,000 from ICH Capital for its subsidiary LongevityBank, which focuses on autologous therapies [3][4] - The strategic vision for LongevityBank is to leverage personalized cellular banking services while CytoMed concentrates on donor-derived allogeneic therapies, which are currently undergoing clinical trials in Singapore and India [2][5] - ICH Capital's investment reflects a belief in the future of healthcare through cell banking and autologous therapies, with plans to explore joint ventures in cancer care centers in Southeast Asia [4] Company Developments - CytoMed is conducting an IND Phase I clinical trial for its allogeneic gamma delta T cell platform in Singapore, with a focus on expanding into the Chinese market following new regulatory pathways for cell therapies [5][7] - The company is in discussions with Chinese firms to develop cost-effective methods for manufacturing donor-derived allogeneic gamma delta T cells [6] - CytoMed's proprietary technologies, including gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, are aimed at creating novel immunotherapies for various cancers [8][9]